StacksMay 18, 20249 min read

Ipamorelin + CJC-1295: The Gold Standard GH Stack

Why combining a GHRP with a GHRH creates synergistic growth hormone release that exceeds either peptide alone.

PA
PepArchive Research Team
Medically reviewed by Medical Review Team
Updated December 10, 2024
9 min read

The Science of Synergy

If you've researched growth hormone peptides, you've likely encountered the Ipamorelin + CJC-1295 (no DAC) combination. This pairing has become the gold standard for GH enhancement—and for good reason. The synergy between these two peptides isn't just additive; research suggests it may be multiplicative.

Understanding the Mechanism

To appreciate why this combination works, you need to understand how natural GH release occurs:

  • The hypothalamus releases GHRH (Growth Hormone Releasing Hormone)
  • GHRH stimulates the pituitary to release GH
  • Ghrelin (from the stomach) provides an additional "release" signal
  • Somatostatin provides a "brake" signal
Ipamorelin mimics ghrelin, hitting the gas pedal. CJC-1295 mimics GHRH, providing the primary release signal. When both signals occur together, the pituitary responds more robustly than to either alone.

Why These Specific Peptides?

Ipamorelin was chosen over other GHRPs because:

  • Most selective GHRP available

  • Doesn't significantly raise cortisol

  • Doesn't affect prolactin

  • Minimal hunger stimulation

  • Clean, consistent GH release


CJC-1295 without DAC (Mod GRF 1-29) was chosen because:
  • Pulsatile release (more physiological)

  • Short half-life matches natural patterns

  • No prolonged GH elevation (which can be problematic)

  • Better synergy with GHRPs than DAC version


The Synergy Effect

Research on GHRP + GHRH combinations has consistently shown:

  • Combined use produces 5-10x more GH than either alone

  • Peak GH levels are higher

  • Duration of elevation is extended

  • The response is more consistent


This isn't unique to Ipamorelin + CJC-1295, but this particular combination offers the cleanest hormone profile among the options.

Typical Research Protocols

Standard Protocol:

  • Ipamorelin: 100-200 mcg

  • CJC-1295 no DAC: 100-200 mcg

  • Combined in same injection

  • 1-3 times daily

  • Best on empty stomach (2+ hours after eating)

  • Wait 30+ minutes before eating after


Timing Strategies:
  • Before bed: Amplifies natural nighttime GH spike

  • Morning: Supports daytime GH and cortisol patterns

  • Pre-workout: Some research suggests benefits for exercise


What to Expect

Based on research and user reports:

Week 1-2: Improved sleep quality (often the first noticeable effect)

Week 3-4: Better recovery from exercise, potential skin improvements

Week 8-12: Body composition changes may become noticeable

Ongoing: Cumulative effects on body composition, sleep, and recovery

Considerations

While this stack has a favorable profile, consider:

  • GH-related water retention is possible initially

  • Tingling/numbness can occur (transient)

  • Best results require consistent dosing

  • Diet and exercise significantly influence outcomes


Comparison to Other Approaches

vs. HGH: Less potent but stimulates natural GH; maintains pulsatility; lower cost
vs. Single Peptide: Significantly more effective; synergy provides better value
vs. GHRP-6 stacks: Cleaner profile; less hunger; less cortisol

The Bottom Line

Ipamorelin + CJC-1295 represents the refined evolution of GH peptide research. It provides robust GH stimulation through synergistic mechanisms while minimizing the side effects that plagued earlier peptide combinations.

For researchers interested in GH enhancement, this remains the standard against which other protocols are measured.

Peptides Mentioned in This Article

Frequently Asked Questions

The no-DAC version (Mod GRF 1-29) provides pulsatile GH release similar to natural patterns. The DAC version creates prolonged elevation which is less physiological and may reduce synergy with GHRPs.
They should be taken together for maximum synergy. The combination effect requires both signals to reach the pituitary simultaneously.

References

  1. Bowers CY. "GHRP + GHRH synergy." J Clin Endocrinol Metab, 1998. PMID: 9768674
  2. Raun K, et al. "Ipamorelin selectivity." Eur J Endocrinol, 1998. PMID: 9758455

Get the Complete Peptide Guide

Join 50,000+ researchers with access to our comprehensive peptide resource.

Free Peptide Guide

Get instant access to our comprehensive research guide.

No spam. Unsubscribe anytime.